바로가기메뉴

본문 바로가기 주메뉴 바로가기

Late-Onset Distant Metastatic Upper Urinary Tract Urothelial Carcinoma Mimicking Lung Adenocarcinoma

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2013, v.75 no.1, pp.32-35

Sang-Hoon Jeon (Inha University)
Jeong Min Lee (Inha University School of Medicine)






  • Downloaded
  • Viewed

Abstract

Urothelial carcinomas (UCs) can occur in the upper urinary tract or lower urinary tract. Upper urinary tract urothelial carcinoma (UUT-UC) is relatively a rare disease and accounts for only about 5% of UC cases. Sporadic cases of late-onset metastasis, associated with UC of the bladder, have occasionally been reported. In contrast, no late-onset distant metastatic UUT-UC without local recurrence has, to the best of our knowledge, been reported in the English literature. We report an extremely rare case of distant metastatic UC, mimicking lung adenocarcinoma that originated from UUT-UC 12 years previously.

keywords
Carcinoma, Urothelium, Urinary Tract, Adenocarcinoma of Lung

Reference

1.

Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584-94.

2.

Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology 1997;50:321-9.

3.

Seymour JE, Malin JM Jr, Pierce JM Jr. Late metastases of a superficial transitional cell carcinoma of the bladder: report of a case. J Urol 1972;108:277-8.

4.

Dougherty DW, Gonsorcik VK, Harpster LE, Trussell JC, Drabick JJ. Superficial bladder cancer metastatic to the lungs: two case reports and review of the literature. Urology 2009;73:210.e3-5.

5.

Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594- 601.

6.

Sengelov L, Kamby C, von der Maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 1996;155:111-4.

7.

Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000;164: 1523-5.

8.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol 2011;29:2432-8.

9.

Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 2009;22 Suppl 2:S96-118.

10.

Nigwekar P, Amin MB. The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Adv Anat Pathol 2008;15:218-33.

11.

Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-30.

12.

Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006;125:675-81.

13.

Mukhopadhyay S, Katzenstein AL. Subclassification of nonsmall cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.

14.

Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.

Tuberculosis & Respiratory Diseases